Alkermes Announces Notification of Tentative FDA Advisory Committee Meeting to Review VIVITROL® for Opioid Dependence

Published June 18, 2010

Alkermes Announces Notification of Tentative FDA Advisory Committee Meeting to Review VIVITROL® for Opioid Dependence
WALTHAM, Mass.—-Alkermes, Inc. today announced that the U.S. Food and Drug Administration has notified the company of the tentative scheduling of a Psychopharmacologic Drugs Advisory Committee meeting on September 16, 2010, for the review of the company’s supplemental New Drug Application for VIVITROL® for opioid dependence.